Is dose normalization to weight or body surface area useful in adults?

Journal of the National Cancer Institute

Volumn 82, Issue 4, 1990, Pages 323-325

  Crochow, Louise B ^a   Baraldi, Carole ^a   Noe, Dennis ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREQUINAR; BUSULFAN; DICHLOROMETHOTREXATE; HEXAMETHYLENEBISACETAMIDE; MENOGARIL; N METHYLFORMAMIDE; OXANTHRAZOLE; PACLITAXEL; TRIMETREXATE;

BODY SURFACE; BODY WEIGHT; CANCER CHEMOTHERAPY; DRUG DOSE; HUMAN; LETTER; METHODOLOGY; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; BODY WEIGHT; HUMAN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025250254     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/82.4.323     Document Type: Letter

References (23)

1. DAWSON WT: Relations between age and weight and dosage of drugs. Ann Intern Med 13:1594-1613, 1940
2. CRAWFORD JD, TERRY ME, ROURKE GM: Simplification of drug dosage calculation by application of the surface area principle. Pediatrics 5:783-789, 1950
3. PINKEL D: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 18:853-856, 1958
4. OWENS AH: Predicting anticancer drug effects in man from laboratory animal studies. J Chronic Dis 15:223-228, 1962
5. FREIREICH EJ, GEHAN EA, RALL DP, et al: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219-244, 1966
6. GOLDSMITH MA, SLAVIK M, CARTER SK: Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 35:1354-1364, 1975
7. LONGNECKER SM, DONEHOWER RC, CATES AE, et al: High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase 1 trial. Cancer Treat Rep 71:53-54, 1987
8. ROWINSKY EK, ETTINGER DS, GROCHOW LB, et al: Phase I and pharmacologic study of hexamethylene bisacetamide (HMBA) in patients with advanced cancer. J Clin Oncol 4:1836-1844, 1986
9. BROWN TD, DONEHOWER RC, GROCHOW LB, et al: A phase I study of menogaril (NSC 269148) in patients with advanced cancer. J Clin Oncol 5:92-99, 1987
10. DONEHOWER TC, ROWINSKY EK, GROCHOW LB, et al: Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 71:1171-1177, 1987
11. ROWINSKY ED, ETTINGER DS, MCGUIRE WP, et al: Prolonged infusion of hexamethylene bisacetamide: A phase I and pharmacologic study. Cancer Res 47:5788-5795, 1987
12. ROWINSKY EK, NOE DA, ORR DW, et al: Clinical pharmacology of oral and intravenous V-methylformamide: A pharmacologic basis for lack of clinical antineoplastic activity.YJatl Cancer Inst 80:671-678, 1988
13. HANTEL A, ROWINSKY EK, NOE DA, et al: Clinical and pharmacologic reappraisal of dichloromethotrexate. J Natl Cancer Inst 80:1547-1553, 1988
14. GROCHOW LB, NOE DA, DOLE GB, et al: Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: Clinical pharmacology and pharmacodynamics. J Natl Cancer Inst 81:124-130, 1989
15. ROWINSKY EK, GROCHOW LB, HANTEL A, et al: Reassessment of n-methyl formamide administered orally on a three times weekly schedule: A phase I study. Invest New Drugs 7:317-325, 1990
16. GROCHOW LB, JONES RJ, BRUNDRETT RB, et al: Pharmacokinetics of busulfan: Correlation with veno occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25:55-61, 1990
17. GROCHOW LB, NOE DA, ETTINGER DS, et al: A phase I trial of trimetrexate glucuronate (NSC 352122) every three weeks: Clinical pharmacology and pharmacodynamics. Cancer Chemother Pharmacol 24:314-320, 1990
18. HANTEL A, NOE DA, GROCHOW LB, et al: A phase I and pharmacokinetic study of oxantrazole (OAZ). Proc ASCO 7:66, 1988
19. DONEHOWER RC, Vrro B, NOE DA, et al: A phase I and pharmacokinetic study of brequinar. Proc ASCO 7:65, 1988
20. ABERNETHY DR, GREENBLATT DJ: Drug disposition in obese humans: An update. Clin Pharmacokinet 11:199-213, 1986
21. EVANS WE, RELLING MV: Clinical pharmacokinetics- pharmacodynamics of anticancer drugs. Clin Pharmacokinet 16:327-336, 1989
22. Powis G, REECE P, AHMANN DL, et al: Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 20: 219-222, 1987
23. RODVOLD KA, RUSHING DA, TEWKSBURY DA: Doxorubicin clearance in the obese. J Clin Oncol 6:1321-1327, 1988